Core Technology 01

Suppresses Metastasis 

Penetrium™ suppresses metastasis by addressing failures in drug delivery.

Core Technology 02

Normalizes the ECM Barrier 

Penetrium™ removes ECM barrier to restore tumor accessibility for both therapeutics and immune cells. 

Core Technology 03

Restores Treatment Response 

Penetrium™ reactivates the efficacy of chemotherapy, targeted therapy, and immunotherapy. 

01. 

ECM Barrier in the Tumor Microenvironment (TME) 

A stiffened ECM limits immune cell infiltration and restricts drug delivery within tumors. 

02. 

Cold Tumors & Fibrotic Tumor Formation 

Low responsiveness to immunotherapy, especially in fibrotic tumors, remains a major challenge. 

03. 

Limitation of Conventional Anticancer Therapies 

Repeated treatment and ECM reinforcement can lead to reduced therapeutic response. 

Alleviation of ECM Stiffness 

Improves immune cell accessibility by reducing ECM stiffness.

Promotion of T Cell Infiltration

Enhances T cell infiltration and immune recognition in immune-excluded tumors.

Inhibition of EMT

Suppresses epithelial–mesenchymal transition (EMT).

Combination Therapy Enabled

Can be co-administered with immune checkpoint inhibitors such as Keytruda and Opdivo.